Cases of hepatitis B and C hit 325 million: WHO

An estimated 325 million people are living with hepatitis B or C and few are aware of their condition, with death tolls from the viruses rising, the UN said Friday. The World Health Organization's latest hepatitis report identifies the condition as a grave public health threat that needs an "urgent response." Hepatitis killed 1.34 million people in 2015, a toll roughly in-line with HIV and tuberculosis. But in contrast to HIV and TB, hepatitis death

WHO prequalifies first generic active ingredient for hepatitis C medicines

On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir. Sofosbuvir is an essential ingredient for new, highly effective medicines to treat hepatitis C called direct active antivirals (DAAs). The prequalified product’s manufacturer is Mylan Laboratories Ltd - INDIA. The emergence of DAAs in 2014 gave new hope to the 80-110 million people suffering from chronic hepatitis C, a disea

Universal Health Coverage—looking to the future

Editorial: The Lancet Volume 388, No. 10062, p2837, 10 December 2016 DOI: http://dx.doi.org/10.1016/S0140-6736(16)32510-7 Universal Health Coverage (UHC) is defined by WHO and the World Bank as when “all people receive the health services they need without suffering financial hardship when paying for them”. UHC is central to the UN Sustainable Development Goals (SDGs), adopted in September, 2015, with a specified target in SDG 3—ensure healthy lives and

First WHO prequalified hepatitis C rapid test opens the door to expanded treatment

WHO has just prequalified its first hepatitis C virus (HCV) rapid diagnostic test, a tool that will aid diagnosis of HCV in low- and middle-income countries and improve access to treatment. [Note: This is not an oral swab] “The fact that we now have very effective new medicines for HCV needs to be bolstered by effective and affordable diagnostics,” said Dr Suzanne Hill, WHO Director for Essential Medicines and Health Products. “This new quality-assured te

Over 1 million treated with highly effective hepatitis C medicines

High prices–a major barrier to access News release 27 October 2016 | GENEVA - Over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago. When Direct Acting Antivirals (DAAs) were first approved for hepatitis C treatment in 2013, there were widespread fears that their high price would put them out of reach for the more than 80 million people w

Prisons: The Problem and Solution of Hepatitis C?

Hepatitis C is curable; however, getting rid of the infection does not take away accompanying liver risks. In addition, many people who are infected don’t even know it – making eradication a distant, but possible, future. Peter Vickerman, BSc, DPhil, from Bristol University’s Division of Global Public Health, and colleagues from the University of New South Wales (UNSW) in Australia looked at a population in which transmission is common and learned s

A Comprehensive And Fair Solution To The Price Of Medicines

After a long dry spell, the pharmaceutical research industry has brought to market a spate of innovative treatments that can extend life and often have fewer side effects than older treatments. But these medicines are not affordable to most of the people who need them. Recent treatments for hepatitis C and cancer - both widespread conditions globally - can cost from $50,000 annually to well over $150,000. Amid public outcry, political battles and medi

New recommendations in the updated WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

BackgroundThe World Health Organization (WHO) issued the first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014. Since then, several new medicines for the treatment of HCV infection have been introduced. These medicines are transforming the treatment of HCV, enabling the use of regimens that can be administered orally, are shorter in duration (as short as eight weeks), result in cure rates higher than 90%, and

World Health Organization VIRAL HEPATITIS Resolution passes

Read the unanimous UN/WHO resolution in full here: http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_R18-en.pdf From IP-Watch article: "The resolution asks states to consider using the flexibilities endorsed in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to promote access to specific pharmaceutical products. The director general is also asked to provide necessary technical support to countries, in